Healthcare News
The latest Healthcare coverage from hundreds of sources, newest first.
Healthcare news covers drugmakers, biotech companies, medical device makers, health insurers and hospital operators.
Stories here include clinical trial results, FDA approvals and rejections, drug pricing policy, patent disputes, and deals in which large drugmakers buy or license from smaller biotechs. A trial readout or an FDA decision can double a small biotech's share price or halve it in one session, which makes this one of the most event-driven parts of the market. Medicare and Medicaid policy is covered here because it sets the revenue outlook for insurers and hospital chains, as is the market for weight-loss drugs, which now drives a large share of results at the companies that make them.
A story is listed here when our topic model tags it Healthcare. Each story's page links to the reports it draws on.
- Last 7 days
- 12 stories
- Previous 7 days
- 11 stories
- Latest story
- Market Flux Event
Nkarta Reports NKX019 Cell Therapy Safety Data in 40 Autoimmune Patients at ACR Convergence 2026
Nkarta presented initial safety and clinical data for NKX019, its investigational allogeneic CAR natural killer cell therapy, at the American College of Rheumatology Convergence 2026…
- Most Active
PepGen Phase 2 DM1 Trial Shows 46.5% Splicing Correction, Stock More Than Doubles
PepGen Inc. reported positive Phase 2 FREEDOM2-DM1 results for its drug PGN-EDODM1 in myotonic dystrophy type 1, sending shares up more than 100% in a single session. The 10 mg/kg cohort…
- Top Story
Dozens of Biotech and Healthcare Companies Present Pipeline and Growth Updates Across Four Major Investor Conferences
On November 10, 2026, a broad cross-section of biotech and healthcare companies presented at four simultaneous investor conferences: the 3rd Annual Guggenheim Healthcare Innovation…
- Market Flux Event
PepGen Stock More Than Doubles on Phase 2 Data Showing Record Splicing Correction in Rare Muscle Disease
PepGen shares surged more than 114% in premarket trading on November 10 after the company reported positive topline results from the 10 mg/kg dose cohort of its Phase 2 FREEDOM2-DM1 trial…
- Market Flux Event
Eli Lilly Foundayo Obesity Pill Cuts Sleep Apnea Disruptions by 44% in Phase 3 Trial Ahead of FDA Filing
Eli Lilly reported positive Phase 3 results for Foundayo, its once-daily oral GLP-1 drug, showing significant reductions in breathing disruptions for adults with moderate-to-severe…
- Market Flux Event
Capital Rotating Into Healthcare Sector as Defensive Play for 2027, with XLV Leading Large ETFs
Investors are shifting capital into the healthcare sector as a defensive alternative to volatile technology and artificial intelligence trades heading into 2027, according to analysis…
- Top Story
FDA Orders Vision-Loss Warning Labels on GLP-1 Drugs Including Ozempic and Zepbound
The U.S. Food and Drug Administration on November 9 ordered the makers of blockbuster GLP-1 drugs to add warnings about a rare but potentially permanent eye condition to their product…
- Market Flux Event
Novartis Abandons Pelacarsen After Phase 3 Trial Shows No Benefit Over Placebo, Dashing Blockbuster Hopes
Novartis is abandoning pelacarsen, an experimental heart drug developed with Ionis Pharmaceuticals, after the drug failed its pivotal late-stage clinical trial. The Phase 3 Lp(a)HORIZON…
- Market Flux Event
J&J's Once-Daily Icotrokinra Pill Shows Significant Benefit in Psoriatic Arthritis as Argenx Posts Phase 3 Win in Autoimmune Myositis
Johnson and Johnson announced that ICOTYDE (icotrokinra), its once-daily targeted oral peptide that blocks the IL-23 receptor, delivered significant improvement in psoriatic arthritis…
- Most Active
Starling Oncology Stock Drops 32% After Q3 Earnings Miss and Cautious 2026 Guidance
Starling Oncology shares fell roughly 32.1% on Friday after the company reported third-quarter 2026 results and issued full-year guidance that disappointed investors. The oncology services…
- Market Flux Event
Eli Lilly Partners With Hims & Hers to Sell Zepbound and Foundayo Directly Through Telehealth Platform
Eli Lilly has struck a direct-to-consumer distribution deal with Hims & Hers Health, allowing the telehealth platform to offer two of Lilly's FDA-approved GLP-1 weight-loss medicines at…
- Most Active
Sanofi Terminates SAR448272 STAT6 Degrader Program, Sending Nurix Stock Down 35%
Nurix Therapeutics shares plunged roughly 28 to 38 percent on November 4, 2026, after Sanofi notified the company it was discontinuing the Phase 1 first-in-human clinical trial of…
- Market Flux Event
Nurix Shares Plunge 35% After Sanofi Terminates Oral STAT6 Degrader SAR448272, While BeOne Medicines Wins FDA Priority Review for BRUKINSA in Frontline Mantle Cell Lymphoma
Nurix Therapeutics shares tumbled roughly 34-38% in after-hours and premarket trading after Sanofi notified the company it was discontinuing the Phase 1 first-in-human clinical trial of…
- Market Flux Event
Rockwell Medical Acquires Vantive Hemodialysis Unit for 125 Million Dollars as Seres Posts Strong Trial Data
Rockwell Medical agreed to acquire Vantive's hemodialysis business for 125 million dollars, sending its shares up 14.3 percent in premarket trading on November 3. The deal expands…
- Top Mover
Abbott Laboratories Reports Strong Cardiovascular Device Trial Data at TCT Conference
Abbott Laboratories presented positive clinical trial results for two investigational cardiovascular devices at the Transcatheter Cardiovascular Therapeutics conference in San Diego on…
- Market Flux Event
FDA Grants uniQure Priority Review for First Huntington's Gene Therapy While Inovio Wins Accelerated Approval for Rare Airway Disease
The FDA accepted uniQure's Biologics License Application for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease, under the Accelerated Approval pathway and…
- Market Flux Event
Teva Drops Phase 2 Trial of Emrusolmin for Multiple System Atrophy After Futility Analysis
Teva Pharmaceutical Industries is discontinuing its Phase 2 TOPAS-MSA study of emrusolmin, also known as TEV-'286, a drug candidate targeting multiple system atrophy, a rare and fatal…
- Market Flux Event
FDA Grants Accelerated Approval to Inovio's Voceryq for Rare Respiratory Disease, Sending Shares Up More Than 280%
The US Food and Drug Administration on October 30 granted accelerated approval to Inovio Pharmaceuticals' Voceryq, formerly known as INO-3107, as an immunotherapy to reduce the frequency of…
- Most Active
NRx Pharmaceuticals Wins FDA Approval for Generic Preservative-Free Ketamine KETAFREE Ahead of Deadline
NRx Pharmaceuticals received FDA approval on October 30 for its generic preservative-free ketamine injection, branded as KETAFREE, beating the agency's November 10 GDUFA goal date. The…
- Market Flux Event
Acumen Pharmaceuticals halts Alzheimer's drug sabirnetug after Phase 2 ALTITUDE-AD trial fails
Acumen Pharmaceuticals is ceasing development of sabirnetug, its lead Alzheimer's candidate, after the Phase 2 ALTITUDE-AD trial missed its primary endpoint and key secondary endpoints. The…
- Market Flux Event
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Ahead of November 10 Deadline
NRx Pharmaceuticals received FDA approval for its generic preservative-free ketamine injection, branded as KETAFREE, on October 30, beating the agency's November 10 GDUFA goal date. The…
- Top Story
Iovance Reports 24.6% Response Rate in Lung Cancer TIL Trial and Adds Precision Strategy
Iovance Biotherapeutics reported updated data from its IOV-LUN-202 registrational trial showing a 24.6% objective response rate across 69 patients with non-squamous metastatic non-small…
- Most Active
Geron Halts Phase 3 IMpactMF Myelofibrosis Trial on Futility Finding, Shares Sink More Than 20%
Geron Corporation has discontinued its Phase 3 IMpactMF clinical trial evaluating imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis after an independent Data…
- Market Flux Event
Genmab Stock Hits All-Time High as Petosemtamab Cuts Head and Neck Cancer Death Risk by 50% in Phase 3 Trial
Genmab shares surged as much as 21% in Copenhagen on Wednesday, hitting an all-time high on the NASDAQ and marking the stock's biggest single-day gain in more than 14 years, after its…
- Market Flux Event
Eli Lilly's Retatrutide Delivers More Than Double the Weight Loss of Ozempic in Phase 3 Diabetes Trial
Eli Lilly's investigational drug retatrutide produced more than twice the average weight loss of Novo Nordisk's Ozempic at its highest approved dose in an 80-week Phase 3 trial enrolling…
Show 25 more
- Market Flux Event
Pfizer ELREXFIO Beats Standard of Care in Phase 3 Multiple Myeloma Trial as AbbVie Files for FDA Approval of Rival Drug
Pfizer reported that its bispecific antibody ELREXFIO (elranatamab) met the primary endpoint of progression-free survival in the Phase 3 MagnetisMM-32 trial, outperforming three established…
- Market Flux Event
Moderna Stock Slides Another 8% as CEO Bancel Touts Cancer Vaccine Potential Beyond Melanoma
Moderna shares fell an additional 8% on October 26, extending a steep selloff that began days earlier when leaked data from the Phase 3 INTerpath-001 trial of its personalized mRNA cancer…
- Market Flux Event
Xencor XmAb819 Posts 45.5% Response Rate in Kidney Cancer Trial, FDA Accelerated Approval Talks Planned for 2027
Xencor's XmAb819, a potential first-in-class ENPP3 x CD3 bispecific T-cell engager, delivered a 45.5% confirmed objective response rate at its proposed 400 mcg/kg intravenous dose in a…
- Most Active
Xencor Selects 400 mcg/kg Phase 3 Dose for XmAb819 After Kidney Cancer Trial Shows 45.5% Response Rate
Xencor reported Phase 1 expansion-cohort data for XmAb819, its ENPP3 x CD3 T-cell engaging bispecific antibody, at the ESMO Congress 2026, selecting 400 mcg/kg as the proposed Phase 3 dose…
- Market Flux Event
Amgen and AstraZeneca Combo Cuts Death Risk 58% in Small Cell Lung Cancer as ESMO 2026 Produces Wave of Oncology Data
Amgen and AstraZeneca reported landmark Phase 3 results at the European Society for Medical Oncology Congress 2026 in Madrid showing that Imdelltra, Amgen's tarlatamab-dlle, combined with…
- Market Flux Event
AstraZeneca Stomach Cancer Drug Sonesitatug Vedotin Doubles Survival Time in Phase III Trial
AstraZeneca's experimental antibody-drug conjugate sonesitatug vedotin, known as Sone-Ve, doubled overall survival time for patients with advanced stomach cancer in a late-stage clinical…
- Market Flux Event
Moderna and Merck mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk 42% in First Phase 3 Win as Oncology Data Flood ESMO 2026
Moderna and Merck reported that their personalized mRNA cancer vaccine, intismeran autogene (mRNA-4157), combined with Merck's Keytruda, reduced the risk of melanoma death or recurrence by…
- Market Flux Event
Amgen and AstraZeneca Drug Combo Cuts Death Risk by 58% in Aggressive Lung Cancer Trial
A combination of Amgen's Imdelltra and AstraZeneca's Imfinzi reduced the risk of death by 58% in patients with first-line extensive-stage small cell lung cancer, one of the most aggressive…
- Market Flux Event
ESMO 2026 Delivers Wave of Oncology Trial Data Including Strong Results in Pancreatic and Lung Cancer
Multiple cancer drug developers presented significant clinical trial data at the European Society for Medical Oncology Congress 2026 in Madrid, with the most closely watched results coming…
- Market Flux Event
Zymeworks Licenses Lung Cancer Drug ZW209 to Roche in Deal Worth Up to $813 Million
Zymeworks has signed a global license and collaboration agreement with Roche granting Roche exclusive worldwide rights to develop and commercialize ZW209, its experimental trispecific…
- Most Active
FDA Accepts Biohaven's Vyglxia NDA Resubmission, Setting Q1 2027 Decision Date for Rare Ataxia Drug
Biohaven Ltd. shares surged after the FDA accepted the company's resubmitted new drug application for Vyglxia (troriluzole), a treatment for spinocerebellar ataxia, with a PDUFA target…
- Unusual Volume
Moderna Loses $24 Billion in Market Value After Phase 3 Melanoma Vaccine Data Leaks Two Days Early
Moderna shares plunged as much as 25% on Thursday, erasing roughly $24 billion in market value, after partial data from its closely watched Phase 3 melanoma vaccine trial leaked on social…
- Market Flux Event
SeaStar Medical QUELIMMUNE Therapy Shows Statistically Significant Survival Benefit in Pediatric Sepsis-Associated AKI Registry
SeaStar Medical Holding Corporation (Nasdaq: ICU) announced statistically significant survival findings from the post-approval QUELIMMUNE SAVE Surveillance Registry in critically ill…
- Market Flux Event
Moderna Loses $24 Billion in Market Value After Melanoma Vaccine Data Leaks on Social Media Two Days Early
Moderna shares plunged as much as 25% on Thursday after partial data from its closely watched Phase 3 melanoma vaccine trial, developed jointly with Merck, leaked on social media ahead of a…
- Market Flux Event
FDA Accepts Biohaven Vyglxia Resubmission for Spinocerebellar Ataxia With Q1 2027 Decision Date
Biohaven shares surged roughly 25-33% in premarket trading on October 22 after the FDA accepted the company's resubmitted new drug application for Vyglxia (troriluzole) in spinocerebellar…
- Market Flux Event
AbbVie Lutikizumab Hits Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trial
AbbVie's lutikizumab met its primary endpoint in a phase 3 clinical trial for hidradenitis suppurativa, a chronic and debilitating inflammatory skin disease, the company announced on…
- Market Flux Event
Arcus Biosciences Drops 20% After Kidney Cancer Data Presentation and New Stock Offering
Arcus Biosciences fell roughly 20% on Wednesday after the company launched a new common stock offering the day after hosting an investor event in New York City on October 20 that presented…
- Market Flux Event
Pope Leo XIV Cleared After Lung Cancer Surgery, No Further Treatment Needed
Pope Leo XIV does not need any additional cancer therapies following surgery last week to remove a cancerous nodule from his right lung, the Vatican press office announced on October 21…
- Top Mover
Bristol Myers Squibb Rises 5% as Cancer Pipeline Wins Draw Investors Amid Patent Cliff Concerns
Bristol Myers Squibb shares climbed 5% on Tuesday, October 20, outperforming most competitors on a strong day for the broader healthcare sector, which hit record highs. The rally came as…
- Market Flux Event
Sun Pharma UNLOXCYT Wins NCCN Preferred Status as Chardan Healthcare Conference Draws Biotech Cohort
Sun Pharmaceutical Industries announced that UNLOXCYT (cosibelimab-ipdl), its PD-L1 checkpoint inhibitor, has received a Category 2A Preferred designation in the updated National…
- Market Flux Event
Moderna Surges 7% Ahead of Phase 3 Melanoma Vaccine Readout as Healthcare Sector Hits Record Highs
Healthcare stocks led Wall Street higher on Tuesday, October 20, with the sector hitting record highs and Eli Lilly touching a new all-time high. Moderna shares jumped 7% to $241, drawing…
- Market Flux Event
Rapport Therapeutics Surges More Than 50% After Bipolar Mania Drug Meets All Trial Goals
Rapport Therapeutics shares jumped more than 50% on October 20 after the company announced that RAP-219 met both primary and secondary endpoints in a Phase 2 trial enrolling 253 adults with…
- Market Flux Event
FDA Approves GSK Rectal Cancer Drug While Veradermics Hair Loss Pill Shows Strong Phase III Results
GSK's Jemperli (dostarlimab-gxly) received FDA approval as the first and only immunotherapy cleared for adults with mismatch repair deficient and microsatellite instability-high locally…
- Most Active
EyePoint Pharmaceuticals Shares Crater 84% as Second DURAVYU Phase 3 Trial Fails in Wet AMD, Triggering 53% Workforce Cut
EyePoint Pharmaceuticals reported that its LUCIA trial, the second pivotal Phase 3 study of DURAVYU in wet age-related macular degeneration, failed to achieve its primary endpoint, dealing…
- Unusual Volume
Disc Medicine Surges 60% After Bitopertin Hits All Phase 3 APOLLO Endpoints in Rare Sun-Sensitivity Disease
Disc Medicine shares rocketed as much as 60% on October 19 after the company announced that its investigational drug bitopertin met all primary and secondary endpoints in the pivotal Phase…